effects of arsenic trioxide on minor progressive high-grade osteosarcoma of the extremities metastatic to the lung: results of 39 patients treated in a single institution

Clicks: 259
ID: 226432
2016
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #49 of 83 articles by views in multi-span large bridges - proceedings of the international conference on multi-span large bridges, 2015

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Patients who mildly progressed after first-line chemotherapy were administered arsenic trioxide (ATO) 5–10 mg intravenously daily. Thirty-nine patients were finally enrolled in the study, of whom 19 patients received first-line chemotherapy with ATO infusion while 20 patients did not. Progression-free survival at 4 months was 89.2 and 62.7% (p = 0.043) for the ATO group and the control group, respectively, while the 2-year overall survival was 61 and 16.4% (p = 0.032).
Reference Key
xie2016caseeffects Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;Lu Xie;Wei Guo;Xiaodong Tang;Yi Yang;Jie Xu
Journal multi-span large bridges - proceedings of the international conference on multi-span large bridges, 2015
Year 2016
DOI
10.1159/000448705
URL
http://www.karger.com/Article/FullText/448705
Keywords
osteosarcoma Oncology including cancer and carcinogens tumors

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.